CTLA4 and pachyonychia congenita: In a phase II clinical trial, 27 patients with PC did not respond to the treatment of anti-CTLA-4 monoclonal antibody Ipilimumab [9]; in another phase I trial using anti-PD-L1 monoclonal antibody, 14 patients with PC showed disappointing responses to the monotherapy [10].